黄金城游戏

Oxford Global Conference’s 10^th Annual Biomarkers Congress saw over 250 delegates working within the biomarker field come together to discuss the latest in biomarker research, companion diagnostics, personalised medicine and clinical biomarkers. The 黄金城游戏 took place on the 23^rd and 24^th February and was held at the Manchester Central Convention Complex. Renowned for its location this prestigious event celebrated its tenth year running. A champagne toast was held after the first day of presentations to celebrate the continue of its success.

Presentations included:

       ·Five Years Of Collaborative Safety Biomarker Qualification: Output Of The IMI SAFE-T Consortium, Michael Merz, Project Coordinator IMI SAFE-T consortium, Novartis Institutes for BioMedical Research

       ·Incorporating Biomarkers In Early Phase Trial Design, James Matcham, Head, Early Clinical Biometrics, AstraZeneca

       ·Clinical Biomarker Development and Validation: Challenges and Solutions, Elena Izmailova, Senior Director, Takeda

       ·Biomarker Discovery And Translational Research By Multi-Omics, Yoshiya Oda, Unit President of Biomarkers & Personalized Medicine Core Function Unit, Eisai Inc.

Senior level delegates came together to discuss current research and exchange experience and knowledge from within the industry. The 黄金城游戏 brought great opportunity for networking and many solution providers were impressed with the high level calibre of the delegates a Sales Specialist from ProteinSimple told us  “I was impressed by the high calibre of all the attendees; it was nice to meet with so many large pharma company decision makers.”

Many of our solution providers benefited from pre-arranged one to one meetings. The senior director from Quintiles praised Oxford Global on the organisation and running of the networking breaks, “The 1-2-1 meetings were very well organised, and I enjoyed the breaks allocated for networking. The exhibition room had a great set up, ideal for delegates visiting the booths.”

Delegates enjoyed the organisation and format of the 黄金城游戏, the director of translational science from 9999AstraZeneca told us “I thought the timing of the presentations and networking sessions worked really well. The inclusion of talks from multiple disease areas in each session was a great idea.”  And the Vice President of Translational Medicine from arGEN-X BVBA said “There was a great mix of scientific and technical presentations. I liked that there was plenty of Solution Providers to network with during the breaks.”

The director of translation Medicine and Clinical Pharmacology from Daiichi Sankyo Development told us how impressed they were with the number of delegates attending the 黄金城游戏 “I was impressed with the number of delegates attending the 黄金城游戏, indicating to me that this is a well-respected 黄金城游戏 and therefore a valued meeting to attend.”

Following the event, we analyse statistics and feedback from attendees, and we are proud to announce that we achieved an “Above Average” or “Excellent” rating in all categories including:

        ·     Relevance and Quality of the Delegates and Solution Providers

        ·     Organisation of the One-to-one Meetings

        ·     Format and Content of the Congress Agenda

This is great news for everyone involved in the production of the 10^th Annual Biomarkers Congress.

After the success of this year’s event, Oxford Global Conferences are pleased to announce that we will be hosting our 11^th Annual Biomarkers Congress in Manchester in February 2016. For further information on attending or sponsoring the event, please contact Danielle Dalby on +44 1865 248455 or by email on [email protected]